目的 觀察千金黃連片對高脂高糖致糖耐量異常模型大鼠的治療作用。方法 選用4～6周齡的雄性SD大鼠90只，隨機選取10只作為對照組，剩余大鼠喂飼高脂高糖飼料，連續(xù)喂飼5個月，測定對照組及模型組大鼠糖負荷（2.5 g·kg^-1）后0.5 h血糖值，挑選糖耐量異常的大鼠［0.5 h血糖值＞8.5 mmol·L^-1及0.5 h血糖值、血糖曲線下面積（AUC）均顯著大于對照組］70只隨機分為7組：模型組、鹽酸二甲雙胍片（125 mg·kg^-1）組、金芪降糖片（2.1 g·kg^-1）組、辛伐他汀組（0.8 mg·kg^-1）和千金黃連片高、中、低劑量（生藥6.50、3.25、1.60 g·kg^-1）組，ig給藥，給藥體積10 mL·kg^-1，每天給藥1次，連續(xù)給藥28 d，對照組與模型組給予等量去離子水。觀察千金黃連片給藥1次對糖耐量的影響及給藥多次對糖耐量、胰島素耐量、淀粉耐量、血脂的影響：①糖耐量：禁食但不禁水12 h后，各組ig給予2.5 g·kg^-1的葡萄糖，分別測定給予葡萄糖前、給予葡萄糖后30、60、120 min各組大鼠血糖水平并計算AUC；②胰島素耐量：動物不禁食，測定給胰島素前血糖，各組sc給予5 U·kg^-1的胰島素溶液，測定給予胰島素后45、90、180 min各組大鼠的血糖水平并計算AUC；③淀粉耐量：禁食但不禁水16 h后，各組ig給予2.5 g·kg^-1的淀粉糊，分別測定給淀粉前、給予淀粉后30、60、120 min各組大鼠血糖水平。于連續(xù)給藥4周后檢測大鼠血清三酰甘油（TG）、總膽固醇（TC）、高密度脂蛋白-膽固醇（HDL-C）、低密度脂蛋白-膽固醇（LDL-C）水平。結(jié)果 與模型組比較，千金黃連片給藥1次、給藥1周、給藥3周能顯著降低高脂高糖致糖耐量異常大鼠糖負荷后血糖水平及AUC（P＜0.05、0.01、0.001） ；給藥3周能使胰島素降血糖作用顯著增強（P＜0.05、0.01）；給藥4周能顯著降低淀粉負荷后血糖（P＜0.05、0.01），顯著降低血清TG、LDL-C水平（P＜0.01、0.001）。結(jié)論 千金黃連片能顯著地改善糖耐量異常；增強胰島素敏感性，改善胰島素抵抗；顯著降低血清TG、LDL-C水平，改善脂質(zhì)代謝異常。其降血糖作用與鹽酸二甲雙胍片相當(dāng)，強于金芪降糖片，其改善胰島素抵抗、增加胰島素敏感性的作用強于鹽酸二甲雙胍片和金芪降糖片，調(diào)節(jié)血脂的作用與鹽酸二甲雙胍片、辛伐他汀相當(dāng)。

Objective To observe the therapeutic effect of Qianjin Huanglian Pill (QJ) on prediabetes. Methods Ninety male SD rats aged from 4 to 6 weeks were selected and 10 were randomly selected as control group. The remaining rats were fed with high-fat and high-sugar diet for five months continuously. The blood glucose level at 0.5 h after glucose load (2.5 g·kg^-1) in control group and model group was measured. Seventy rats with abnormal glucose tolerance [0.5 h blood glucose>8.5 mmol·L^-1 and 0.5 h blood glucose and AUC were significantly higher than control group] were randomly divided into seven groups: Model group, Metformin hydrochloride tablet (125 mg·kg^-1) group, Jingqi Jiangtang tablet (2.1 g·kg^-1) group, simvastatin group (0.8 mg·kg^-1) and JQ highdose, medium-dose and low-dose (crude drug 6.50, 3.25, 1.60 g·kg^-1) groups, ig, 10 mL·kg^-1, once a day for 28 d, control group and model group were given the same amount of deionized water. To observe the effect of QJ once administration on glucose tolerance and the effect of multiple administration on glucose tolerance, insulin tolerance, starch tolerance and blood lipid. ① Glucose tolerance: After fasting for 12 h without water restriction, each group was given 2.5 g·kg^-1 glucose intragastrically, and the blood glucose levels were determined before, 30, 60 and 120 min after glucose administration, and the AUC was calculated. ② Insulin tolerance: Without fasting, blood glucose was measured before insulin administration, 5 U·kg^-1 insulin solution was sc in each group. Blood glucose levels of rats in 45, 90 and 180 min after insulin administration were measured and AUC was calculated. ③ Starch tolerance: After fasting but without water for 16 h, each group was given starch paste 2.5 g·kg^-1 intragaally, and blood glucose levels were determined before starch administration, 30, 60 and 120 min after starch administration. The levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (LDL-C) and low density lipoprotein-cholesterol (LDL-C) were detected in blood samples after four weeks of continuous administration. Results Compared with the model group, administration of QJ for once, one week and three weeks could significantly reduce blood glucose of rats after glucose loaded (P<0.05, 0.01, and 0.001). Administration of QJ for three weeks could significantly enhance the hypoglycemic effect of insulin (P<0.05 and 0.01). Administration of QJ for four weeks could significantly reduce blood glucose of rats after starch loaded (P<0.05 and 0.01) and serum TG and LDL levels (P<0.05 and 0.001). Conclusion QJ could significantly improve IGT, enhance insulin sensitivity, improve insulin resistance (IR), significantly reduce serum TG and LDL levels and improve abnormal lipid metabolism. Its hypoglycemic effect is comparable to that of metformin, which is stronger than that of Jinqi Jiangtang Tablet. Its effect of improving insulin resistance and increasing insulin sensitivity is stronger than that of metformin and Jingqi Jiangtang tablet. Its effect of regulating blood lipids is similar to that of metformin and simvastatin.

R285.5

國家科技重大專項(2019ZX09201005-001-002);國家中醫(yī)藥管理局中醫(yī)藥國際合作專項(0610-2140NF020630)